AFP and hepatocellular carcinoma: We previously demonstrated that the combination of the ALBI grade (2 vs. 1) and AFP level (≥20 ng/mL) could stratify patients with unresectable HCC (uHCC) for sorafenib–regorafenib sequential therapy [32].